Beijing Tiantan Biological Products Co., Ltd.
600161
Kedudukan dalam Saham
#4320
Beijing Tiantan Biological Products Co., Ltd., established in 1998 and... Beijing Tiantan Biological Products Co., Ltd., established in 1998 and headquartered in Beijing, China, is actively involved in the full spectrum of blood product operations within China. This includes pioneering research and development, manufacturing, sales, and providing consultancy services. Its comprehensive product line features critical blood-derived medicines such as intravenous immunoglobulin, human albumin, and various specialized human immunoglobulins for conditions like hepatitis B (both standard and freeze-dried formulations) and tetanus, alongside other general human immunoglobulin preparations and intravenous blood system solutions. The company operates as a subsidiary of China National Biotec Group Company Limited.
Harga Saham
$1.81
Modal Pasaran
$3.59B
Perubahan (1 hari)
-0.90%
Perubahan (1 tahun)
-32.39%
Negara
CN
Perdagangan Beijing Tiantan Biological Products Co., Ltd. (600161)
Kategori
Healthcare
Hasil untuk Beijing Tiantan Biological Products Co., Ltd. (600161)
Hasil pada Oct 2026 TTM: 0
Menurut laporan kewangan terkini daripada Beijing Tiantan Biological Products Co., Ltd., hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Beijing Tiantan Biological Products Co., Ltd. dari 2001 hingga 2026
Hasil pada akhir setiap tahun
| Tahun | Hasil | Ubah |
|---|---|---|
| 2025 | $877.40M | 6.17% |
| 2024 | $826.38M | 12.92% |
| 2023 | $731.85M | 18.47% |
| 2022 | $617.77M | -4.52% |
| 2021 | $646.98M | 22.66% |
| 2020 | $527.44M | 11.91% |
| 2019 | $471.31M | 10.61% |
| 2018 | $426.11M | 11.64% |
| 2017 | $381.67M | 23.92% |
| 2016 | $308.00M | 23.62% |
| 2015 | $249.16M | -15.51% |
| 2014 | $294.89M | -2.60% |
| 2013 | $302.76M | 25.67% |
| 2012 | $240.92M | 8.92% |
| 2011 | $221.19M | 21.43% |
| 2010 | $182.15M | 13.03% |
| 2009 | $161.16M | 61.08% |
| 2008 | $100.05M | 37.71% |
| 2007 | $72.66M | 37.07% |
| 2006 | $53.01M | 24.61% |
| 2005 | $42.54M | 21.37% |
| 2004 | $35.05M | 18.43% |
| 2003 | $29.59M | 22.68% |
| 2002 | $24.12M | 28.78% |
| 2001 | $18.73M | 0.00% |
Hasil untuk syarikat atau pesaing serupa
| Syarikat | Hasil | Perbezaan Hasil | Negara |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| - | - |
CH
|
